Global role of the immune system in identifying cancer initiation and limiting disease progression

Journal of Clinical Oncology

Volumn 23, Issue 35, 2005, Pages 8923-8925

  Disis, Mary L ^a   Lyerly, H Kim ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CANCER VACCINE; IMMUNOSUPPRESSIVE AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UTERINE CERVIX CANCER; ARTICLE; DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 33644802938     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.007     Document Type: Review

References (15)

1. Preuss KD, Zwick C, Bormann C, et al: Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188:43-50, 2002
2. Wang X, Yu J, Sreekumar A, et al: Autoantibody signatures in prostate cancer. N Engl J Med 353:1224-1235, 2005
3. Zhang L, Conejo-Garcia JR, Katsaros D, et al: lntratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003
4. Peoples GE, Gurney JM, Hueman MT, et al: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536-7545, 2005
5. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274, 2005
6. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217, 2005
7. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-8064, 2005
8. Lake RA, Robinson BW: Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5:397-405, 2005
9. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296-306, 2005
10. Sosman JA, Unger JM, Liu PY, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node- negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075, 2002
11. Peoples GE, Gurney JM, Hueman MT, et al: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol, 2005
12. Koutsky LA, Ault KA, Wheeler CM, et al: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651, 2002
13. Villa LL, Costa RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278, 2005
14. Comoli P, Pedrazzoli P, Maccario R, et al: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23:8942-8949, 2005
15. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005